ZNF655

ZNF655 is a Krüppel-type C2H2 zinc-finger transcription factor that promotes cell-cycle progression and cell survival by directly activating transcription of proliferative and oncogenic target genes. It shuttles between nucleus and cytoplasm via dedicated NLS/NES sequences, interacts with Vav-1 and CDK4, and its overexpression inhibits G1 progression in a manner rescued by Vav-1 co-expression (PMID:15558030). ZNF655 directly binds promoters of AURKA and ANKHD1, cooperates with E2F1 to activate CDK1 transcription, and facilitates MAFF nuclear translocation to drive CCND1 expression (PMID:35280721, PMID:35927248, PMID:32464549, PMID:41088232). Across multiple cancer types and neuronal injury models, ZNF655 sustains PI3K/Akt signaling and suppresses apoptosis, linking its transcriptional activity to pro-survival pathway output (PMID:34144060, PMID:41352639).

1. 2005 Medium

   The initial identification of ZNF655 (VIK-1) established it as a nucleo-cytoplasmic shuttling Krüppel-like zinc-finger protein that physically engages Vav-1 and CDK4 and modulates G1 cell-cycle progression, answering what the gene product is and how it connects to cell-cycle control.

   Evidence Yeast two-hybrid screen, domain mapping, subcellular localization, and cell-cycle analysis in Jurkat-derived system

   PMID:15558030

   Open questions at the time

   • No direct DNA-binding target or transcriptional activity demonstrated
   • Cell-cycle inhibition by overexpression not reconciled with later pro-proliferative roles
   • Vav-1 and CDK4 interactions not validated by endogenous co-IP
2. 2020 Medium

   Demonstration that ZNF655 binds the ANKHD1 promoter to repress its transcription, and that ZNF655 mRNA is itself degraded via Staufen1-mediated decay triggered by LINC00346, established ZNF655 as a bona fide transcription factor embedded in a lncRNA feedback loop.

   Evidence Luciferase reporter, RIP, SMD assays, and loss/gain-of-function in glioma-associated endothelial cells in vitro and in vivo

   PMID:32464549

   Open questions at the time

   • ANKHD1 promoter binding demonstrated by reporter but ChIP-level confirmation not shown
   • Generalizability of the SMD feedback loop to non-endothelial contexts unclear
3. 2021 Low

   Knockdown studies in NSCLC placed ZNF655 upstream of PI3K/Akt signaling and apoptotic regulators, revealing a broader pro-survival signaling role beyond direct transcriptional targets.

   Evidence shRNA knockdown with Western blot profiling of Akt, CDK6, PIK3CA, p21, p27, caspases in NSCLC cells

   PMID:34144060

   Open questions at the time

   • Pathway positioning inferred from expression changes without direct binding or reconstitution
   • No identification of direct transcriptional targets mediating PI3K/Akt activation
   • Single-lab study
4. 2022 Medium

   ChIP and reporter assays proved ZNF655 directly activates the AURKA promoter and cooperates with E2F1 at the CDK1 promoter, defining two key mitotic-kinase targets through which ZNF655 drives proliferation in glioma and pancreatic cancer.

   Evidence ChIP-qPCR, luciferase reporters, co-IP of ZNF655–E2F1, functional rescue by AURKA or CDK1 knockdown

   PMID:35280721 PMID:35927248

   Open questions at the time

   • DNA-binding motif or genome-wide binding profile not defined
   • Whether ZNF655–E2F1 interaction is direct or bridged by co-factors is unresolved
   • Relevance of these targets in non-cancer physiology unknown
5. 2023 Low

   Identification of PSMB8 as a downstream effector in hepatocellular carcinoma expanded the repertoire of ZNF655-regulated genes, though direct transcriptional regulation was not established.

   Evidence Overexpression/knockdown rescue experiments in HCC cell lines

   PMID:37272200

   Open questions at the time

   • No ChIP or reporter assay to confirm direct promoter binding of PSMB8
   • Single-lab functional data without independent replication
6. 2025 Medium

   Two studies extended ZNF655 function: one showed ZNF655 promotes MAFF nuclear translocation and CCND1 transcription in ovarian cancer conferring paclitaxel resistance, the other showed ZNF655 activates Akt/Nrf2 antioxidant signaling in neurons, broadening ZNF655's role from an oncogenic factor to a general pro-survival transcriptional regulator.

   Evidence ChIP of MAFF on CCND1 promoter, subcellular fractionation, xenografts (ovarian cancer); adenoviral overexpression, Akt inhibitor/Nrf2 siRNA epistasis in OGD/R neuronal model

   PMID:41088232 PMID:41352639

   Open questions at the time

   • How ZNF655 promotes MAFF nuclear translocation mechanistically is unknown
   • Direct binding of ZNF655 to Akt pathway components not demonstrated
   • Nrf2 axis role relies on pharmacological/siRNA epistasis without direct interaction data

• The genome-wide binding landscape and consensus DNA-binding motif for ZNF655 remain undefined, and how its early-described G1-inhibitory phenotype relates to its consistently observed pro-proliferative role in cancer contexts is unresolved.
• No ChIP-seq or equivalent genome-wide binding data available
• The structural basis for target promoter selectivity is unknown
• Physiological (non-cancer) function of ZNF655 has not been addressed in knockout models